Innovative Therapeutics Sigilon focuses on developing immune-protected, engineered human cell therapies aimed at providing functional cures for acute and chronic diseases, creating opportunities to collaborate with healthcare providers and organizations seeking advanced, transformative treatment options.

Strategic Acquisition Eli Lilly's recent $310 million acquisition of Sigilon indicates a strong commitment to expanding its portfolio in cell-based therapeutics, opening doors for partnership and licensing opportunities in the growing field of regenerative medicine.

Collaborative Development Since 2018, Sigilon has partnered with Lilly on encapsulated-cell therapies for diseases such as type 1 diabetes, demonstrating a proven track record of successful collaborations that can be leveraged for new joint ventures or co-development projects.

Funding & Growth With over $145 million in funding and revenue in the $10M to $25M range, Sigilon is well-positioned for expansion, providing potential sales opportunities for suppliers, service providers, and investors aiming to engage with innovative biotech companies in growth phases.

Focus on Chronic Diseases Sigilon’s emphasis on creating universal, immune-protected therapies for diseases without fibrosis or rejection addresses a significant market need, representing a substantial opportunity for organizations providing enabling technologies, specialized materials, or complementary therapeutic solutions.